secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001437749-25-038773
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 2.06, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell pauses Re-Tain after FDA incomplete letter, shifts focus to First Defense; $2.3M impairment
--------------------------------------------------------------------------------

- FDA issued Incomplete Letter for Re-Tain NADA on Dec 23 due to contract manufacturer inspection issues; four of five Technical Sections had Complete Letters.
- ImmuCell pauses further investment in Re-Tain; will complete studies and seek to license or partner the product.
- Non-cash impairment write-down of ~$2.3M on Re-Tain property, plant and equipment in Q4 2025.
- First Defense sales force increased by 50%, new U.S. territories created, international senior dairy executive to be hired.
- First Defense revenue grew from ~$4.4M to ~$27.8M (TTM Sep 30, 2025) with >13% CAGR over 15 years; targeting $900M global TAM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774925038773/0001437749-25-038773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774925038773/iccc20251224_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-038773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer